

Aprepitant capsules and Lidocaine/prilocaine cream

- o On March 9, 2023, Sandoz announced a consumer level recall of two lots of aprepitant 125 mg capsules and nine lots of lidocaine/prilocaine 2.5%/2.5% cream because the packaging is not child-resistant as required by the Poison Prevention Packaging Act, posing a risk of harm if children ingest the drugs or put the cream on their skin.
- o The recall is not a result of any quality or safety concerns with the medications for their intended use, so consumers should continue using the medication as directed by their physicians. However, due to the risk of harm to children, consumers should immediately secure the medication out of the sight and reach of children.

Product Description	NDC#	Lot# (Expiration Date)
Aprepitant 125 mg capsules	0781-2323-68 (carton)	LK3209 (4/2024)
	0781-2323-06 (blister pack)	LC6454 (12/2023)
Lidocaine/prilocaine 2.5%/2.5% cream	0168-0357-56 (carton); 0168-0357-55 (carton); 0168-0357-05 (tube)	LA2782 (3/2023); LA2784 (3/2023); LV0667 (3/2024); LX5350 (3/2024); MA1640 (3/2024); MB3205 (4/2024); LA2785 (3/2023); LR9041 (11/2023); MB3209 (4/2024)

- o Aprepitant capsules are indicated for the prevention of chemotherapy induced nausea and vomiting and for the prevention of postoperative nausea and vomiting.
- o Lidocaine and prilocaine cream is indicated as a topical anesthetic for use on normal intact skin for local analgesia and for use on genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia.
- o Anyone with an existing inventory of the recalled product should contact Sandoz at 1-866-300- 2207, to order a free child-resistant, resealable pouch in which to store the medication.

- o Contact Sandoz at 1-800-525-8747 for questions regarding this recall.